Recursion Pharmaceuticals rises as positive Phase 1b/2 trial results for REC-4881 validate AI-driven drug discovery platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
IEEE

Recursive Deformable Pyramid Network for Unsupervised Medical Image Registration

Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...
Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
IEEE

Deadlock Resolution and Recursive Feasibility in MPC-Based Multirobot Trajectory Generation

Abstract: Online collision-free trajectory generation within a shared workspace is fundamental for most multirobot applications. However, many widely-used methods based on model predictive control ...
Reuters

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Yahoo Finance

Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data Release - What's Changed

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...